美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ATYR PHARMA INC

0.8748

-0.0520-5.61%

成交量：51.30萬

成交額：45.94萬

市值：8,571.87萬

市盈率：-1.04

高：0.9181

開：0.9100

低：0.8523

收：0.9268

52周最高：7.29

52周最低：0.6400

股本：9,798.66萬

流通股本：9,596.60萬

量比：0.97

換手率：0.53%

股息：- -

股息率：- -

每股收益(TTM):-0.8425

每股收益(LYR):-0.8621

淨資產收益率：-103.49%

總資產收益率：-49.59%

市淨率：1.07

市盈率(LYR):-1.01

資料載入中...

總覽公司新聞資訊公告

Atyr Pharma, Inc.盤中異動快速拉升5.71%

ATYR PHARMA INC 宣佈安排與美國FDA進行C類會議，討論Efzofitimod治療肺結節病項目

Atyr Pharma, Inc.盤中異動股價大漲5.00%報0.698美元

Atyr Pharma, Inc.盤中異動股價大漲5.16%報0.685美元

Atyr Pharma, Inc.盤中異動下午盤股價大跌5.02%報0.920美元

Atyr Pharma, Inc.盤中異動臨近收盤快速下跌6.05%

異動解讀 | ATYR製藥公司股價夜盤大漲23.15%後暴跌81.8%，肺病新藥試驗失敗

異動解讀 | aTyr Pharma股價盤後大跌5.32%，肺部疾病藥物在後期研究中未達主要目標

aTyr Pharma Inc：Leerink Partners將評級從跑贏大盤下調至與大盤持平，目標價從16美元下調至1美元

異動解讀 | aTyr Pharma股價盤中暴跌81.84%，肺病新藥後期臨牀試驗失敗

異動解讀 | aTyr Pharma股價盤前暴跌79.77%，肺病新藥後期試驗未達主要目標

BUZZ-aTyr因肺病藥物在後期研究中未能達到主要目標而暴跌

aTyr Pharma 的肺病藥物在後期試驗中未能達到主要目標

aTyr Pharma宣佈Efzofitimod治療肺結節病的第3期Efzo-Fit™研究頂線結果

Atyr Pharma, Inc.盤中異動大幅拉升5.15%

aTyr Pharma宣佈根據納斯達克上市規則5635(C)(4)授予激勵股權

Atyr Pharma, Inc.盤中異動早盤急速下挫5.08%報5.42美元

異動解讀 | ATYR PHARMA盤中大漲8.11%，業績低於預期但長期前景樂觀

Atyr Pharma, Inc.盤中異動急速拉升5.47%

異動解讀 | ATYR PHARMA股價盤前大漲7.17%，儘管季度業績未達預期

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ATYR/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATYR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":0.8748,"timestamp":1770913962838,"preClose":0.9268,"halted":0,"volume":513032,"delay":0,"changeRate":-0.05610703495899864,"floatShares":95966000,"shares":97986634,"eps":-0.842499,"marketStatus":"交易中","change":-0.052,"latestTime":"02-12 11:33:37 EST","open":0.91,"high":0.9181,"low":0.8523,"amount":459378.56962608,"amplitude":0.070997,"askPrice":0.8801,"askSize":1529,"bidPrice":0.8752,"bidSize":468,"shortable":3,"etf":0,"ttmEps":-0.842499,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1770930000000},"marketStatusCode":2,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":0.9268,"preHourTrading":{"tag":"盘前","latestPrice":0.9102,"preClose":0.9268,"latestTime":"09:24 EST","volume":7255,"amount":6666.9585987,"timestamp":1770906282116,"change":-0.0166,"changeRate":-0.017911,"amplitude":0.044238},"postHourTrading":{"tag":"盘后","latestPrice":0.9268,"preClose":0.9268,"latestTime":"19:48 EST","volume":7990,"amount":7334.6258,"timestamp":1770857291120,"change":0,"changeRate":0,"amplitude":0.027622},"volumeRatio":0.974045,"impliedVol":0.6952,"impliedVolPercentile":0.0837},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","floatShares":95966000,"roa":"-49.59%","roe":"-103.49%","lyrEps":-0.862131,"volumeRatio":0.974045,"shares":97986634,"dividePrice":0,"high":0.9181,"amplitude":0.070997,"preClose":0.9268,"low":0.8523,"week52Low":0.64,"pbRate":"1.07","psRate":"451.15","week52High":7.2904,"institutionHeld":0,"latestPrice":0.8748,"committee":-0.531297,"eps":-0.842499,"divideRate":0,"volume":513032,"delay":0,"ttmEps":-0.842499,"open":0.91,"prevYearClose":0.7831,"prevWeekClose":0.899,"prevMonthClose":0.8828,"prevQuarterClose":0.7831,"fiveDayClose":0.8107,"twentyDayClose":0.7179,"sixtyDayClose":0.7532},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATYR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"ATYR","fiscalQuarterEnding":"2025/09","expectedEps":-0.2,"name":null,"time":"盤後","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2025-08-07","symbol":"ATYR","fiscalQuarterEnding":"2025/06","expectedEps":-0.18,"name":null,"time":"盤後","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2025-05-07","symbol":"ATYR","fiscalQuarterEnding":"2025/03","expectedEps":-0.19,"name":null,"time":"盤後","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":-0.17},{"market":"US","date":"2025-03-13","symbol":"ATYR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"盤後","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2024-11-07","symbol":"ATYR","fiscalQuarterEnding":"2024/09","expectedEps":-0.22,"name":null,"time":"盤後","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.23}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATYR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATYR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1,"buy":0.2,"hold":0.7,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.7,"analysts":10,"updateTime":1762578000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ATYR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ATYR","date":"2026-02-10","current":-1.100061,"percent":0.835411,"low":-9.277729,"twenty":-5.263462,"median":-4.035211,"eighty":-1.413283,"high":-0.849664,"avg":-3.828184,"sd":2.268553,"marketCap":88138977},"quantilePoints":[{"date":"2024-06-07","current":-2.380173,"twenty":-2.380173,"median":-2.380173,"eighty":-2.380173,"marketCap":128360348},{"date":"2024-06-14","current":-2.367376,"twenty":-2.482546,"median":-2.431359,"eighty":-2.377614,"marketCap":127670239},{"date":"2024-06-21","current":-2.021867,"twenty":-2.446715,"median":-2.367376,"eighty":-2.203579,"marketCap":109037285},{"date":"2024-06-28","current":-1.970681,"twenty":-2.431359,"median":-2.367376,"eighty":-2.111444,"marketCap":106276847},{"date":"2024-07-05","current":-1.970681,"twenty":-2.431359,"median":-2.265003,"eighty":-1.991155,"marketCap":106276847},{"date":"2024-07-12","current":-2.073054,"twenty":-2.39041,"median":-2.092249,"eighty":-1.970681,"marketCap":111797722},{"date":"2024-07-15","current":-2.226613,"twenty":-2.380173,"median":-2.111444,"eighty":-1.970681,"marketCap":120079035},{"date":"2024-08-02","current":-2.495343,"twenty":-2.421122,"median":-2.130639,"eighty":-1.9758,"marketCap":134571333},{"date":"2024-08-09","current":-2.380173,"twenty":-2.403207,"median":-2.265003,"eighty":-1.996274,"marketCap":128360348},{"date":"2024-08-16","current":-2.618312,"twenty":-2.418704,"median":-2.296995,"eighty":-2.001393,"marketCap":151592396},{"date":"2024-08-23","current":-2.448121,"twenty":-2.445503,"median":-2.341783,"eighty":-2.021867,"marketCap":141738890},{"date":"2024-08-30","current":-2.474305,"twenty":-2.468042,"median":-2.373775,"eighty":-2.032104,"marketCap":143254814},{"date":"2024-09-06","current":-2.291023,"twenty":-2.461213,"median":-2.354579,"eighty":-2.073054,"marketCap":132643346},{"date":"2024-09-13","current":-2.448121,"twenty":-2.474305,"median":-2.380173,"eighty":-2.111444,"marketCap":141738890},{"date":"2024-09-20","current":-2.448121,"twenty":-2.474305,"median":-2.399368,"eighty":-2.149834,"marketCap":141738890},{"date":"2024-09-27","current":-2.277931,"twenty":-2.474305,"median":-2.382664,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-04","current":-2.277931,"twenty":-2.469749,"median":-2.373775,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-11","current":-2.77541,"twenty":-2.474305,"median":-2.382664,"eighty":-2.251748,"marketCap":160687939},{"date":"2024-10-18","current":-3.469263,"twenty":-2.48085,"median":-2.399368,"eighty":-2.251748,"marketCap":200859924},{"date":"2024-10-25","current":-4.241665,"twenty":-2.500488,"median":-2.421938,"eighty":-2.265003,"marketCap":245579681},{"date":"2024-10-31","current":-4.097658,"twenty":-2.555472,"median":-2.431359,"eighty":-2.275241,"marketCap":237242099},{"date":"2024-11-08","current":-4.058383,"twenty":-2.922036,"median":-2.441575,"eighty":-2.277905,"marketCap":234968213},{"date":"2024-11-15","current":-3.78886,"twenty":-3.621287,"median":-2.448121,"eighty":-2.277931,"marketCap":241789871},{"date":"2024-11-22","current":-3.919838,"twenty":-3.629704,"median":-2.448121,"eighty":-2.277931,"marketCap":250148372},{"date":"2024-11-29","current":-4.643298,"twenty":-3.916561,"median":-2.461213,"eighty":-2.285786,"marketCap":296316696},{"date":"2024-12-06","current":-4.301299,"twenty":-4.007344,"median":-2.474305,"eighty":-2.298878,"marketCap":274491670},{"date":"2024-12-13","current":-3.972453,"twenty":-4.100191,"median":-2.474305,"eighty":-2.31136,"marketCap":253506069},{"date":"2024-12-20","current":-4.143453,"twenty":-4.111931,"median":-2.474305,"eighty":-2.3168,"marketCap":264418582},{"date":"2024-12-27","current":-4.95899,"twenty":-4.144489,"median":-2.487396,"eighty":-2.317206,"marketCap":316462874},{"date":"2025-01-03","current":-5.143143,"twenty":-4.229494,"median":-2.500488,"eighty":-2.317206,"marketCap":328214811},{"date":"2025-01-10","current":-4.919528,"twenty":-4.267848,"median":-2.526671,"eighty":-2.317206,"marketCap":313944602},{"date":"2025-01-17","current":-4.932682,"twenty":-4.327606,"median":-2.579037,"eighty":-2.328986,"marketCap":314784026},{"date":"2025-01-24","current":-4.682759,"twenty":-4.341161,"median":-2.768865,"eighty":-2.330035,"marketCap":298834968},{"date":"2025-01-31","current":-4.919528,"twenty":-4.389843,"median":-2.932509,"eighty":-2.330297,"marketCap":313944602},{"date":"2025-02-07","current":-5.090528,"twenty":-4.509129,"median":-3.510289,"eighty":-2.339486,"marketCap":324857115},{"date":"2025-02-14","current":-4.722221,"twenty":-4.606467,"median":-3.575068,"eighty":-2.341783,"marketCap":301353241},{"date":"2025-02-21","current":-5.827142,"twenty":-4.643298,"median":-3.6107,"eighty":-2.357139,"marketCap":371864863},{"date":"2025-02-28","current":-5.090528,"twenty":-4.682759,"median":-3.851618,"eighty":-2.375054,"marketCap":324857115},{"date":"2025-03-07","current":-4.051376,"twenty":-4.682759,"median":-3.972453,"eighty":-2.380173,"marketCap":258542613},{"date":"2025-03-14","current":-5.248373,"twenty":-4.682759,"median":-3.985607,"eighty":-2.381668,"marketCap":334930203},{"date":"2025-03-21","current":-4.929845,"twenty":-4.727483,"median":-3.990774,"eighty":-2.382664,"marketCap":315623450},{"date":"2025-03-28","current":-4.52461,"twenty":-4.75379,"median":-4.035211,"eighty":-2.388848,"marketCap":289679075},{"date":"2025-04-04","current":-3.872289,"twenty":-4.740636,"median":-4.038222,"eighty":-2.400648,"marketCap":247915527},{"date":"2025-04-11","current":-3.802893,"twenty":-4.727483,"median":-4.011134,"eighty":-2.407615,"marketCap":243472596},{"date":"2025-04-17","current":-4.191509,"twenty":-4.722221,"median":-4.035211,"eighty":-2.414083,"marketCap":268353008},{"date":"2025-04-25","current":-4.788314,"twenty":-4.743267,"median":-4.051376,"eighty":-2.421938,"marketCap":306562211},{"date":"2025-05-02","current":-4.635643,"twenty":-4.743267,"median":-4.087671,"eighty":-2.425706,"marketCap":296787764},{"date":"2025-05-09","current":-4.680309,"twenty":-4.75642,"median":-4.108234,"eighty":-2.431359,"marketCap":296787764},{"date":"2025-05-16","current":-4.210769,"twenty":-4.743267,"median":-4.133647,"eighty":-2.432827,"marketCap":267013308},{"date":"2025-05-23","current":-5.333641,"twenty":-4.774836,"median":-4.143453,"eighty":-2.440266,"marketCap":338216856},{"date":"2025-05-30","current":-5.972275,"twenty":-4.816072,"median":-4.149872,"eighty":-2.448121,"marketCap":378713875},{"date":"2025-06-06","current":-7.509205,"twenty":-4.87282,"median":-4.17922,"eighty":-2.448121,"marketCap":476173732},{"date":"2025-06-13","current":-7.621493,"twenty":-4.919528,"median":-4.191509,"eighty":-2.448121,"marketCap":483294087},{"date":"2025-06-20","current":-7.256559,"twenty":-4.932682,"median":-4.241665,"eighty":-2.448121,"marketCap":460152934},{"date":"2025-06-27","current":-7.453062,"twenty":-4.985297,"median":-4.254757,"eighty":-2.448121,"marketCap":472613555},{"date":"2025-07-03","current":-7.453062,"twenty":-5.016231,"median":-4.28094,"eighty":-2.448121,"marketCap":472613555},{"date":"2025-07-11","current":-7.481134,"twenty":-5.080005,"median":-4.302543,"eighty":-2.458595,"marketCap":474393643},{"date":"2025-07-18","current":-8.126785,"twenty":-5.119466,"median":-4.327606,"eighty":-2.461213,"marketCap":515335684},{"date":"2025-07-25","current":-7.796941,"twenty":-5.18655,"median":-4.339852,"eighty":-2.468042,"marketCap":494419641},{"date":"2025-08-01","current":-6.624944,"twenty":-5.237851,"median":-4.345289,"eighty":-2.473394,"marketCap":420100937},{"date":"2025-08-08","current":-7.354811,"twenty":-5.277498,"median":-4.380221,"eighty":-2.474305,"marketCap":466383244},{"date":"2025-08-15","current":-7.337565,"twenty":-5.711388,"median":-4.396173,"eighty":-2.474305,"marketCap":488953303},{"date":"2025-08-22","current":-7.278747,"twenty":-6.338611,"median":-4.472298,"eighty":-2.474305,"marketCap":485033838},{"date":"2025-08-29","current":-7.866928,"twenty":-6.868599,"median":-4.491152,"eighty":-2.474305,"marketCap":524228491},{"date":"2025-09-05","current":-8.043383,"twenty":-7.051635,"median":-4.498606,"eighty":-2.474305,"marketCap":535986887},{"date":"2025-09-12","current":-7.734587,"twenty":-7.202339,"median":-4.538489,"eighty":-2.478232,"marketCap":515409694},{"date":"2025-09-19","current":-1.543977,"twenty":-7.202339,"median":-4.511608,"eighty":-2.474305,"marketCap":102885965},{"date":"2025-09-26","current":-1.313556,"twenty":-7.183573,"median":-4.496851,"eighty":-2.466335,"marketCap":87531460},{"date":"2025-10-03","current":-1.043875,"twenty":-7.138658,"median":-4.477635,"eighty":-2.448121,"marketCap":69560711},{"date":"2025-10-10","current":-1.401343,"twenty":-7.082514,"median":-4.406529,"eighty":-2.442885,"marketCap":93381262},{"date":"2025-10-17","current":-1.470454,"twenty":-7.051635,"median":-4.382946,"eighty":-2.421938,"marketCap":97986634},{"date":"2025-10-24","current":-1.430458,"twenty":-7.012335,"median":-4.346398,"eighty":-2.388848,"marketCap":95321397},{"date":"2025-10-31","current":-1.305763,"twenty":-6.956191,"median":-4.340306,"eighty":-2.375054,"marketCap":87012130},{"date":"2025-11-07","current":-1.004754,"twenty":-6.884883,"median":-4.327606,"eighty":-2.330297,"marketCap":75479104},{"date":"2025-11-14","current":-0.930535,"twenty":-6.741157,"median":-4.315074,"eighty":-2.317206,"marketCap":69903664},{"date":"2025-11-21","current":-0.849664,"twenty":-6.641787,"median":-4.294031,"eighty":-2.285786,"marketCap":63828493},{"date":"2025-11-28","current":-1.018058,"twenty":-6.613715,"median":-4.254757,"eighty":-2.277852,"marketCap":76478567},{"date":"2025-12-05","current":-1.079755,"twenty":-6.467742,"median":-4.247271,"eighty":-2.236667,"marketCap":81113335},{"date":"2025-12-12","current":-0.998232,"twenty":-6.153338,"median":-4.191509,"eighty":-2.08841,"marketCap":74989171},{"date":"2025-12-19","current":-0.9171,"twenty":-5.941396,"median":-4.17922,"eighty":-1.996274,"marketCap":68894402},{"date":"2025-12-26","current":-0.962753,"twenty":-5.88149,"median":-4.159816,"eighty":-1.970681,"marketCap":72323934},{"date":"2026-01-02","current":-1.02145,"twenty":-5.827142,"median":-4.144316,"eighty":-1.58809,"marketCap":76733333},{"date":"2026-01-09","current":-0.945796,"twenty":-5.68245,"median":-4.143453,"eighty":-1.529272,"marketCap":71050108},{"date":"2026-01-16","current":-0.921535,"twenty":-5.590373,"median":-4.115174,"eighty":-1.499863,"marketCap":69227556},{"date":"2026-01-23","current":-0.973579,"twenty":-5.463588,"median":-4.100824,"eighty":-1.470454,"marketCap":73137223},{"date":"2026-01-30","current":-1.109494,"twenty":-5.353291,"median":-4.058383,"eighty":-1.430928,"marketCap":83347430},{"date":"2026-02-06","current":-1.05745,"twenty":-5.277498,"median":-4.044799,"eighty":-1.420105,"marketCap":79437764},{"date":"2026-02-10","current":-1.173278,"twenty":-5.263462,"median":-4.035211,"eighty":-1.413283,"marketCap":88138977}],"updateTime":1770879219071},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATYR\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609154675","title":"Atyr Pharma, Inc.盤中異動 快速拉升5.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609154675","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609154675?lang=zh_tw&edition=fundamental","pubTime":"2026-02-07 03:11","pubTimestamp":1770405114,"startTime":"0","endTime":"0","summary":"北京时间2026年02月07日03时11分，Atyr Pharma, Inc.股票出现异动，股价大幅上涨5.71%。Atyr Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.82%。Atyr Pharma, Inc.公司简介：aTyr Pharma Inc 是一家生物治疗公司，致力于通过其专有的 tRNA 合成酶平台发现和开发一流的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207031155a6dcaa07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207031155a6dcaa07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"1178762224","title":"ATYR PHARMA INC 宣佈安排與美國FDA進行C類會議，討論Efzofitimod治療肺結節病項目","url":"https://stock-news.laohu8.com/highlight/detail?id=1178762224","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178762224?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 21:03","pubTimestamp":1770123813,"startTime":"0","endTime":"0","summary":"ATYR PHARMA INC 已正式安排与美国食品药品监督管理局（FDA）举行C类会议，重点讨论其候选药物Efzofitimod在肺结节病领域的研发项目。此次会议旨在就该项目的关键开发路径与监管机构进行深入交流。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2586418212","title":"Atyr Pharma, Inc.盤中異動 股價大漲5.00%報0.698美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586418212","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586418212?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 22:33","pubTimestamp":1763994800,"startTime":"0","endTime":"0","summary":"北京时间2025年11月24日22时33分，Atyr Pharma, Inc.股票出现异动，股价大幅拉升5.00%。截至发稿，该股报0.698美元/股，成交量5.4894万股，换手率0.06%，振幅4.50%。Atyr Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。Atyr Pharma, Inc.公司简介：aTyr Pharma Inc 是一家生物治疗公司，致力于通过其专有的 tRNA 合成酶平台发现和开发一流的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223321977cabaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223321977cabaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATYR","KTTA","BK4139"],"gpt_icon":0},{"id":"2585317922","title":"Atyr Pharma, Inc.盤中異動 股價大漲5.16%報0.685美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585317922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585317922?lang=zh_tw&edition=fundamental","pubTime":"2025-11-22 01:54","pubTimestamp":1763747667,"startTime":"0","endTime":"0","summary":"北京时间2025年11月22日01时54分，Atyr Pharma, Inc.股票出现异动，股价大幅上涨5.16%。截至发稿，该股报0.685美元/股，成交量119.212万股，换手率1.22%，振幅6.75%。Atyr Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.98%。Atyr Pharma, Inc.公司简介：aTyr Pharma Inc 是一家生物治疗公司，致力于通过其专有的 tRNA 合成酶平台发现和开发一流的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251122015428a7098337&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251122015428a7098337&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2579210685","title":"Atyr Pharma, Inc.盤中異動 下午盤股價大跌5.02%報0.920美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579210685","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579210685?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 02:14","pubTimestamp":1761848097,"startTime":"0","endTime":"0","summary":"北京时间2025年10月31日02时14分，Atyr Pharma, Inc.股票出现异动，股价大幅跳水5.02%。截至发稿，该股报0.920美元/股，成交量238.338万股，换手率2.43%，振幅4.15%。Atyr Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.82%。Atyr Pharma, Inc.公司简介：aTyr Pharma Inc 是一家生物治疗公司，致力于通过其专有的 tRNA 合成酶平台发现和开发一流的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103102145894e5f739&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103102145894e5f739&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2569974629","title":"Atyr Pharma, Inc.盤中異動 臨近收盤快速下跌6.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569974629","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569974629?lang=zh_tw&edition=fundamental","pubTime":"2025-09-24 03:56","pubTimestamp":1758657380,"startTime":"0","endTime":"0","summary":"北京时间2025年09月24日03时56分，Atyr Pharma, Inc.股票出现异动，股价急速下挫6.05%。Atyr Pharma, Inc.股票所在的生物技术行业中，整体跌幅为1.30%。其相关个股中，木薯科学、Surrozen Inc C/Wts 01/08/2031 、Galecto, Inc.涨幅较大，Galecto, Inc.、Silo Pharma, Inc.、Soligenix, Inc.较为活跃，换手率分别为4050.45%、360.01%、184.71%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、木薯科学、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为68.73%、48.49%、48.46%。Atyr Pharma, Inc.公司简介：aTyr Pharma Inc 是一家生物治疗公司，致力于通过其专有的 tRNA 合成酶平台发现和开发一流的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924035620a6999ee5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924035620a6999ee5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"1137305404","title":"異動解讀 | ATYR製藥公司股價夜盤大漲23.15%後暴跌81.8%，肺病新藥試驗失敗","url":"https://stock-news.laohu8.com/highlight/detail?id=1137305404","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137305404?lang=zh_tw&edition=fundamental","pubTime":"2025-09-16 08:02","pubTimestamp":1757980947,"startTime":"0","endTime":"0","summary":"ATYR制药公司股价在夜盘交易中大涨23.15%后，周一盘中遭遇重创，暴跌81.8%至1.09美元的历史新低。这种剧烈的价格波动源于该公司最新公布的临床试验结果。ATYR制药公司周一宣布，其用于治疗肺肉瘤病的新药efzofitimod在一项后期临床研究中未能达到主要终点。该试验旨在证明，与安慰剂相比，使用efzofitimod的患者在48周后每日类固醇用量的削减幅度更大。这一令人失望的结果对ATYR制药公司的前景造成了严重打击。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ATYR"],"gpt_icon":1},{"id":"1115439695","title":"異動解讀 | aTyr Pharma股價盤後大跌5.32%，肺部疾病藥物在後期研究中未達主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=1115439695","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115439695?lang=zh_tw&edition=fundamental","pubTime":"2025-09-16 05:04","pubTimestamp":1757970263,"startTime":"0","endTime":"0","summary":"aTyr Pharma周一盘后股价大跌5.32%，主要原因是该公司宣布其肺部疾病药物efzofitimod在一项后期研究中未能达到主要目标。根据公司公告，efzofitimod在治疗肺肉瘤病患者的3期临床试验中，未能显示出与安慰剂相比在48周后每日类固醇用量削减幅度上的统计学显著差异。这一结果对aTyr Pharma打击不小，导致其股价在盘后交易中大幅下挫。尽管临床试验结果不如预期，aTyr Pharma表示将与美国食品和药物管理局进行接触，以确定该药物的未来发展方向。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ATYR"],"gpt_icon":0},{"id":"1122596588","title":"aTyr Pharma Inc：Leerink Partners將評級從跑贏大盤下調至與大盤持平，目標價從16美元下調至1美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122596588","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122596588?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 23:33","pubTimestamp":1757950396,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc：Leerink Partners将评级从跑赢大盘下调至与大盘持平，目标价从16美元下调至1美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"1123521217","title":"異動解讀 | aTyr Pharma股價盤中暴跌81.84%，肺病新藥後期臨牀試驗失敗","url":"https://stock-news.laohu8.com/highlight/detail?id=1123521217","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123521217?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 21:48","pubTimestamp":1757944106,"startTime":"0","endTime":"0","summary":"生物制药公司aTyr Pharma周一盘中股价大幅下挫81.84%，创下历史性跌幅。这一暴跌主要源于公司核心产品研发的重大挫折。根据aTyr Pharma最新公布的临床试验结果，其用于治疗肺肉瘤病的实验性药物efzofitimod在后期临床试验中未能达到主要目标。这一结果无疑是对aTyr Pharma的沉重打击。aTyr Pharma此次研发失利，不仅打破了市场对公司开发新型治疗方案的期待，也可能影响公司未来的发展方向。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ATYR"],"gpt_icon":0},{"id":"1125274879","title":"異動解讀 | aTyr Pharma股價盤前暴跌79.77%，肺病新藥後期試驗未達主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=1125274879","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125274879?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 20:30","pubTimestamp":1757939424,"startTime":"0","endTime":"0","summary":"周一盘前交易中，生物制药公司aTyr Pharma股价大幅下跌79.77%，投资者对公司核心产品研发失利反应强烈。根据公司最新公告，aTyr Pharma的实验性药物efzofitimod在针对肺肉瘤病患者的后期临床试验中未能达到主要目标。尽管试验结果不尽如人意，但aTyr Pharma表示，efzofitimod的安全性与先前的研究结果一致。目前，已获批准的肺肉瘤病一线治疗方法主要是皮质类固醇激素，如泼尼松。aTyr Pharma此次研发失利，无疑打击了市场对公司开发新型治疗方案的期待，从而导致股价大幅下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ATYR"],"gpt_icon":0},{"id":"2567111360","title":"BUZZ-aTyr因肺病藥物在後期研究中未能達到主要目標而暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2567111360","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567111360?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 20:12","pubTimestamp":1757938360,"startTime":"0","endTime":"0","summary":"9月15日 - ** 药物开发商aTyr Pharma ATYR.O股价盘前下跌83%至1.01美元** 该公司称其实验性药物efzofitimod在肺肉瘤病患者的晚期研究中没有达到 。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nL3T3V20O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2567116242","title":"aTyr Pharma 的肺病藥物在後期試驗中未能達到主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2567116242","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567116242?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 19:37","pubTimestamp":1757936231,"startTime":"0","endTime":"0","summary":"aTyr Pharma 的肺病药物在后期试验中未能达到主要目标路透社9月15日 - aTyr Pharma ATYR.O周一表示，其实验性药物在一项针对肺肉样肿患者的后期研究中没有达到主要目标。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nL3S3V20M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"1193378701","title":"aTyr Pharma宣佈Efzofitimod治療肺結節病的第3期Efzo-Fit™研究頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1193378701","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193378701?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 19:30","pubTimestamp":1757935859,"startTime":"0","endTime":"0","summary":"aTyr Pharma宣布Efzofitimod治疗肺结节病的第3期Efzo-Fit™研究顶线结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2566997849","title":"Atyr Pharma, Inc.盤中異動 大幅拉升5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566997849","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566997849?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 23:19","pubTimestamp":1757603947,"startTime":"0","endTime":"0","summary":"北京时间2025年09月11日23时19分，Atyr Pharma, Inc.股票出现波动，股价急速上涨5.15%。Atyr Pharma, Inc.股票所在的生物技术行业中，整体涨幅为1.04%。其相关个股中，Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Maze Therapeutics, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Silexion Therapeutics Corp、Gri Bio, Inc.、Kazia Therapeutics Limited较为活跃，换手率分别为2251.40%、2183.07%、199.90%，振幅较大的相关个股有Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Silexion Therapeutics Corp、Gri Bio, Inc.，振幅分别为155.42%、72.91%、58.33%。Atyr Pharma, Inc.公司简介：aTyr Pharma Inc 是一家生物治疗公司，致力于通过其专有的 tRNA 合成酶平台发现和开发一流的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250911231907a71c4cd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250911231907a71c4cd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"1194283090","title":"aTyr Pharma宣佈根據納斯達克上市規則5635(C)(4)授予激勵股權","url":"https://stock-news.laohu8.com/highlight/detail?id=1194283090","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194283090?lang=zh_tw&edition=fundamental","pubTime":"2025-09-06 05:58","pubTimestamp":1757109529,"startTime":"0","endTime":"0","summary":"9月5日 - aTyr Pharma Inc宣布根据纳斯达克上市规则5635(C)(4)授予激励股权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2565472587","title":"Atyr Pharma, Inc.盤中異動 早盤急速下挫5.08%報5.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2565472587","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565472587?lang=zh_tw&edition=fundamental","pubTime":"2025-09-04 22:47","pubTimestamp":1756997262,"startTime":"0","endTime":"0","summary":"北京时间2025年09月04日22时47分，Atyr Pharma, Inc.股票出现波动，股价快速下挫5.08%。Atyr Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.47%。其相关个股中，Lexaria Bioscience Corp C/Wts 14/01/2026 、Novabay Pharmaceuticals, Inc.、冠科美博涨幅较大，Purple Biotech Ltd、Soligenix, Inc.、Novabay Pharmaceuticals, Inc.较为活跃，换手率分别为1559.37%、133.99%、61.27%，振幅较大的相关个股有Apollomics Inc C/Wts 01/04/2028 、冠科美博、Revelation Biosciences Inc C/Wts 10/01/2027 ，振幅分别为36.08%、35.56%、25.68%。Atyr Pharma, Inc.公司简介：aTyr Pharma Inc 是一家生物治疗公司，致力于通过其专有的 tRNA 合成酶平台发现和开发一流的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250904224742a70fe120&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250904224742a70fe120&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"1133718952","title":"異動解讀 | ATYR PHARMA盤中大漲8.11%，業績低於預期但長期前景樂觀","url":"https://stock-news.laohu8.com/highlight/detail?id=1133718952","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133718952?lang=zh_tw&edition=fundamental","pubTime":"2025-08-11 22:06","pubTimestamp":1754921206,"startTime":"0","endTime":"0","summary":"生物制药公司ATYR PHARMA今日盘中大涨8.11%，尽管公司最新公布的季度业绩未达分析师预期。这一涨幅引起了投资者的广泛关注。值得注意的是，ATYR PHARMA的股价在本季度已上涨4.5%，今年迄今为止更是累计上涨了46.4%，显示出强劲的市场表现。分析师对ATYR PHARMA保持看好态度，目前对该公司股票的平均评级为\"买入\"。ATYR PHARMA作为一家专注于tRNA合成酶平台的生物治疗公司，其主要产品efzofitimod在治疗肺部炎症和纤维化方面显示出潜力，这可能是投资者保持乐观的另一个原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ATYR"],"gpt_icon":1},{"id":"2558665507","title":"Atyr Pharma, Inc.盤中異動 急速拉升5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558665507","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558665507?lang=zh_tw&edition=fundamental","pubTime":"2025-08-11 21:37","pubTimestamp":1754919424,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日21时37分，Atyr Pharma, Inc.股票出现异动，股价大幅上涨5.47%。Atyr Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Entero Therapeutics Inc.、Artelo Biosciences, Inc.、Indaptus Therapeutics, Inc.涨幅较大，Entero Therapeutics Inc.、Io Biotech, Inc.、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为2082.58%、79.21%、30.46%，振幅较大的相关个股有Entero Therapeutics Inc.、Io Biotech, Inc.、Nucana Plc，振幅分别为38.56%、14.06%、13.66%。Atyr Pharma, Inc.公司简介：aTyr Pharma Inc 是一家生物治疗公司，致力于通过其专有的 tRNA 合成酶平台发现和开发一流的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213704a6dfba9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213704a6dfba9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"1123968363","title":"異動解讀 | ATYR PHARMA股價盤前大漲7.17%，儘管季度業績未達預期","url":"https://stock-news.laohu8.com/highlight/detail?id=1123968363","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123968363?lang=zh_tw&edition=fundamental","pubTime":"2025-08-11 20:04","pubTimestamp":1754913866,"startTime":"0","endTime":"0","summary":"生物制药公司ATYR PHARMA INC今日盘前股价大涨7.17%，尽管公司最新公布的季度业绩未达分析师预期。这一涨幅引起了投资者的广泛关注。值得注意的是，ATYR PHARMA的股价在本季度已上涨4.5%，今年迄今为止更是累计上涨了46.4%，显示出强劲的市场表现。分析师对ATYR PHARMA保持看好态度，目前对该公司股票的平均评级为\"买入\"。这一乐观预期可能是推动股价上涨的主要原因之一。尽管公司本季度业绩略低于预期，但投资者似乎更加关注其长期增长潜力和行业前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ATYR"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}